Bally’s shares climbed 9% to $10 on Monday, signaling a rare moment of investor optimism after the company secured $560 million in financing commitments. The capital is earmarked for its ambitious $4 billion Bronx resort project, an aggressive expansion plan that has faced significant scrutiny throughout a volatile fiscal year.
A 6% surge in midday trading signaled investor optimism as AeroVironment’s recently acquired BlueHalo unit secured a $99.8 million contract from the U.S. Air Force. The deal marks a significant milestone for the defense firm, which has faced a difficult year with shares sliding 36% since January.
Fomento Económico Mexicano shares climbed 3.1% to $120.62 in Monday afternoon trading after the retail and beverage giant launched an accelerated share repurchase agreement. This move to buy back $280 million in American depositary shares marks a significant milestone for the firm, which has seen its stock gain 19% this year.
BioNTech’s American depositary receipts climbed 3.7% to $110.34 Monday after the company announced its experimental lung cancer treatment, gotistobart, nearly doubled median survival rates in a Phase 3 trial, outperforming standard chemotherapy in patients who had exhausted previous treatment options.
PBF Energy shares tumbled 7% to $72.73 on Monday following the company’s announcement of a $500 million exchangeable notes offering due 2032. Despite the sharp intraday decline, the petroleum refiner’s stock valuation has nearly tripled over the course of this year, reflecting a broader period of significant growth.
Federal energy officials have mandated that TransAlta keep its Centralia Generating Station operational for an additional 90 days, citing an urgent need to maintain grid reliability. This latest directive forces the facility to remain available through December 12, further delaying the long-planned decommissioning of the state's final coal-fired unit.
The neon-lit streets of Las Vegas now serve as the latest testing ground for Alphabet’s autonomous fleet. Waymo confirmed on Monday that it has officially opened its driverless ride-hailing operations to the general public, marking a significant expansion of the company’s reach across the Nevada desert.
Investors pushed Stewards shares down 9% to $2.69 on Monday as the financial platform disclosed fresh details regarding its proposed acquisition of two South Florida multifamily properties. Trading volume surged to 966,000 shares, more than double the company's 65-day average, reflecting heightened market sensitivity to the expansion strategy.
The 10-year U.S. Treasury yield retreated Monday after breaching the 5% threshold for the first time since October 2023, tracking a volatile session in energy markets. Simultaneously, German Bund yields climbed to a 15-year peak of 3.538%, reflecting mounting investor anxiety over the persistence of global inflationary pressures.
Amazon has tapped international capital markets, finalizing the sale of 4.25 billion British pounds in notes. This multi-billion dollar injection, valued at approximately $5.74 billion, underscores the e-commerce giant's strategy to bolster its liquidity through long-term debt instruments maturing between 2029 and 2045.
A veteran of the gaming and private equity sectors, Adam Chibib is set to take the helm as chief financial officer at IGT. His appointment, effective November 1, marks a pivotal shift for the organization as it navigates the post-merger integration of its gaming, digital, and financial technology operations.
With U.S. oil futures climbing past $100 per barrel and diesel prices exceeding $6 a gallon, markets are bracing for a sharp contraction in consumption. The latest price spike follows targeted assaults on Saudi Arabia’s East-West pipeline, effectively choking off a vital bypass route for Persian Gulf crude exports.
Shares of Veea surged 41% in after-hours trading following the announcement of a proposed merger with NovaGen Group. The deal aims to fuse cyber infrastructure with clinical cellular science, creating a new entity called NovaGen Health Networks intended to reshape patient-controlled data and regenerative therapy pathways.
A convergence of cooling enthusiasm for artificial intelligence and a relentless surge in energy prices sent U.S. stocks into a retreat. The market correction arrived as investors braced for an imminent Federal Reserve rate hike while processing a rare plea from industry titans to decelerate the pace of AI development.
A 50% reduction in pSMAD3 proteins among patients treated with AGMB-447 has cleared the path for Agomab Therapeutics to launch a Phase 2 trial. The Belgian biopharmaceutical firm confirmed its candidate successfully inhibited the TGF-beta/ALK5 pathway during early-stage testing for idiopathic pulmonary fibrosis.
The Food and Drug Administration has granted breakthrough therapy designation to Rasonque, a treatment developed by Revolution Medicines for metastatic pancreatic adenocarcinoma. This regulatory milestone aims to accelerate the development timeline for the drug, which is currently being tested in combination with gemcitabine and nab-paclitaxel for patients facing this aggressive cancer.
Veracyte has secured a deal worth up to $180 million to acquire Convergent Genomics, adding the UroAmp urinary tumor DNA platform to its cancer diagnostics lineup. The transaction includes an immediate $150 million cash payment, with the remaining $30 million contingent upon the achievement of specific clinical and commercial milestones.
Shares of Contineum Therapeutics slid 8.2% in after-hours trading Monday, dropping to $13.59, as investors reacted to news that the company's Phase 2 trial for a depression treatment failed to hit its primary efficacy goal. The clinical disappointment casts a shadow over the firm’s pipeline development.
Facing a pivot in its clinical pipeline, Sionna Therapeutics announced a 46% reduction in its workforce this Monday. The biotech firm aims to concentrate its dwindling resources on a dual-drug combination therapy for cystic fibrosis, effectively buying itself a cash runway that extends into late 2029.
A $63.3 million price tag marks the latest expansion for Winter Park-based CTO Realty Growth, which finalized its acquisition of the Zona Rosa mixed-use center in Kansas City, Missouri. The deal translates to approximately $82 per square foot for the retail complex, a strategic play for the Florida-based firm.
A dual-front pressure hit Wall Street as Anthropic CEO Dario Amodei signaled a need to throttle AI development, while oil prices climbed for the ninth time in ten sessions. The Dow Jones Industrial Average dropped 152.09 points, reflecting deepening anxiety over both technological trajectory and resurgent inflation risks.
Economic pressures and the rapid shift toward artificial intelligence have prompted a new alliance in the Southern Hemisphere. Datacom will now provide Rimini Street’s third-party maintenance services to public and private sector clients across Australia and New Zealand, marking a significant expansion for the software support provider in the region.
The 10-year U.S. Treasury yield breached the 5% threshold, triggering a sharp selloff across Asian debt markets. Investors are demanding higher premiums for long-term holdings as rising energy costs and aggressive central bank expectations reshape the global fixed-income landscape, pushing yields to levels unseen in decades.
A sharp downturn hit industrial and transportation sectors today as investors braced for the dual pressure of runaway wholesale inflation and imminent interest rate hikes. Record-high diesel prices are squeezing manufacturing margins, while the prospect of aggressive monetary tightening threatens to further stifle growth across the broader industrial landscape.
A 15% slide in Ocean Power Technologies shares on Monday signaled deep investor unease, coinciding with the abrupt departure of CEO Philipp Stratmann and the announcement of a formal strategic review. The firm, now led by acting chief executive Tracy Pagliara, is hunting for ways to stabilize its cooling financial position.
A sharp 14% plunge in Corning shares highlights growing investor anxiety regarding the artificial intelligence hardware cycle. The drop follows widespread cooling across the raw materials sector, as markets recalibrate to the reality that current infrastructure demand may fail to meet the industry's previously stratospheric projections for growth.
CVS Health is replacing traditional consumer surveys with a massive network of 150,000 artificial intelligence simulations. By partnering with the startup Simile, the retail pharmacy giant creates digital twins of clinicians and patients to stress-test product messaging and adoption strategies with unprecedented speed and precision.
Jereme Sylvain, the financial architect behind DexCom’s recent expansion, is adding oversight of global operations and quality control to his portfolio. The company confirmed Monday that its executive vice president will now serve as both chief financial officer and chief operating officer, consolidating leadership ahead of its next growth phase.
Bally's Corp. locked in $560 million in financing for its proposed Bronx casino while moving to quell skepticism surrounding its Chicago development. The capital injection, spearheaded by WhiteHawk Capital Partners, signals a aggressive push to maintain the company’s ambitious 2027 timeline for its flagship Midwestern property despite recent market volatility.
Ascendis Pharma has officially reclaimed full control over its TransCon technology for metabolic and cardiovascular treatment following the dissolution of its partnership with Novo Nordisk. The move grants the Danish firm exclusive rights to advance its once-monthly semaglutide program independently, alongside a newly authorized $400 million share repurchase plan.
